Biocon Ltd.'s consolidated net profit more than doubled in the fourth quarter of fiscal 2025, beating analysts' estimates.The drugmaker's profit increased to Rs 344 crore in the March quarter, compared to Rs 135 crore in the year-ago period, according to an exchange filing on Thursday. That compares with the Rs 197.9-crore consensus estimate of analysts tracked by Bloomberg.Biocon Q4 Highlights (Consolidated, YoY)Revenue up 13% to Rs 4,417 crore versus Rs 3,917 crore (Bloomberg estimate: Rs 4,133 crore).Ebitda up 18% to Rs 1,078 crore versus Rs 916 crore (Estimate: Rs 933 crore).Margin expands to 24.4% versus 23.4% (Estimate: 22.6%).Profit up 155% to Rs 344 crore versus Rs 135 crore (Bloomberg estimate: Rs 197.9 crore).The company reassessed the value of its inventory following a business acquisition from Viatris. This reassessment revealed that the inventory was worth Rs. 65 crore more than initially estimated, which positively impacted the company's profit.During the fiscal ended March 31, 2024, a subsidiary recognised an exceptional loss due to inventory provisions for slow-moving products. However, during the fiscal ended March 31, 2025, the company recorded an exceptional gain from the reversal of these provisions following inventory liquidation and also recognised an exceptional gain from an insurance claim related to a prior fire incident.These non-recurring events had a significant impact on the company' s year-on-year financial results. Additionally lower taxes also helped profit.GenericsThe generics business delivered a healthy 46% YoY and a robust 53% sequential growth in Q4, concluding FY25 with an overall 8% growth over the previous year. The performance was primarily driven by contributions from new product launches, notably Lenalidomide and Dasatinib in the US, supported by modest growth in the API business.“Looking ahead, we remain focused on the strategic expansion of our differentiated GLP-1 portfolio into new markets, which will position us well for growth," Kiran Mazumdar-Shaw, chairperson of Biocon Group, said. "In FY26, we also expect to see a recovery in the API business, aided by our cost improvement initiatives, enhancement of operational efficiencies, and new capacities coming on-stream."Biocon BiologicsBiocon Biologics continued its growth momentum in Q4 FY25, delivering a robust 9% year-on-year revenue increase, driven by significant market-share gains in the US and key tender wins in emerging markets."On a full-year basis, the company has recorded a strong 15% growth in FY25 and we have successfully consolidated our business worldwide," Chief Executive Officer Shreehas Tambe said. "Having built a strong foundation, we are well-positioned to launch five new products in the next 12–18 months and expand patient access."Syngene InternationalSyngene International reported a Q4 FY25 revenue growth of 11% year-on-year and 8% sequentially, crossing Rs 1,000 crore in a quarter threshold for the first time. At the Ebitda level, growth was 9% YoY, reflecting good underlying fundamentals. The full-year results, led by reported revenue growth of 4%, are in line with company's earlier guidance."Looking at the year ahead, while the wider global market dynamics remain uncertain, the positive momentum that drove Syngene's return to growth in the latter half of FY25 is expected to continue into FY26, with projected revenue growth in the mid-single digits," Peter Bains, CEO of Syngene International, said.Shares of Biocon closed 3.75% lower at Rs 333.5 apiece on the NSE, compared to a 0.58% decline in the benchmark Nifty.Q4 Results Live: Asian Paints Profit Falls 45%, Escorts Kubota Profit Rises 8%